Edwards' TAVR Platforms Challenged In Boston Scientific Patent Suits
This article was originally published in The Gray Sheet
More patent litigation is emerging in the transcatheter aortic valve replacement space with two recent lawsuits alleging that Edwards Lifesciences' Sapien 3 TAVR device and delivery systems violated a total of nine patents held by Boston Scientific.
You may also be interested in...
The US Court of Appeals for the Federal Circuit upheld a Patent Trial & Appeals Board ruling against a doctor who claimed to be the true inventor of technology used in the CoreValve transcatheter aortic heart valve replacement device.
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.
The firm announced the CE mark and European launch of its transcatheter aortic heart valve replacement device Oct. 28. Boston is one of at least seven firms with a TAVR device now on the market in Europe.